Cloning and Mutagenesis Market Growth, Drivers, and Opportunities

Cloning and Mutagenesis Market - Global Forecast 2030

Report Code: UC-HC-6828 Jun, 2025, by marketsandmarkets.com

Cloning and mutagenesis are molecular biology techniques used to manipulate DNA for research, therapeutic, or industrial applications. The cloning and mutagenesis market is mainly driven by factors such as growing advancements in genomic technologies, increasing focus on personalized approach to therapeutics and increasing prevalence of genetic diseases. However, complexity of the techniques employed for cloning and mutagenesis along with few ethical concers are expected to pose challenges to the market growth.

Cloning and mutagenesis market- global forecast to 2030

Cloning and Mutagenesis Market

Global Cloning and Mutagenesis Market Dynamics

DRIVER: Growing advancements in genomic technologies

Advancements in genomic technologies have transformed the field of cloning and mutagenesis, making it a powerful driver for the market. Modern genomic tools have significantly improved the precision and efficiency of cloning and mutagenesis processes. Technologies like DNA printing enable the creation of synthetic genes without requiring a template. This reduces the dependency on natural DNA samples and accelerates cloning workflows. Moreover, Genomic advancements have brought automation and scalability to cloning and mutagenesis. NGS allows rapid verification of cloning and mutagenesis results, ensuring higher accuracy in applications like gene therapy and diagnostics.

RESTRAINT: Complexity of techniques

The complexity of techniques in cloning and mutagenesis acts as a significant restraint to market growth, particularly for smaller organizations or less-experienced users. Many cloning and mutagenesis techniques are intricate and require advanced skills and training. Processes like PCR, restriction digestion, ligation, and transformation demand a deep understanding of molecular biology and biochemistry in case of cloning. Even small errors, such as incorrect primer design or poor reaction conditions, can lead to failed experiments. Mutagenesis requires precision in designing primers and understanding the gene of interest. Achieving site-specific changes without introducing off-target effects can be technically challenging.

Recent Developments:

In May 2022, Qiagen acquired BLIRT, QIAGEN N.V. announced the acquisition of a 96% majority ownership stake in BLIRT S.A., a Gdansk, Poland-based manufacturer of recombinant enzymes for the life science industry. This strategic move aims to enhance QIAGEN's capabilities in enzyme development and production, thereby strengthening its sample technologies and expanding its global presence. The integration of BLIRT's specialized enzyme portfolio is expected to create additional growth opportunities for QIAGEN's existing offerings.
In February 2022, Tamara Bio, Inc., a central hub for cell and general processing in Japan, announced the expansion of its production facilities. The newly established laboratory will focus on manufacturing products such as cancer immunotherapy drugs, gene therapies, DNA and RNA vaccines, and leveraging cloning and mutagenesis techniques for regenerative medicine applications.

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TABLE OF CONTENTS

1 INTRODUCTION

1.1 STUDY OBJECTIVES

1.2 MARKET DEFINITION

1.2.1 INCLUSIONS & EXCLUSIONS OF STUDY

1.3 STUDY SCOPE

1.3.1 MARKETS COVERED

1.3.2 REGIONS COVERED

1.4 YEARS CONSIDERED

1.5 CURRENCY CONSIDERED

1.6 STAKEHOLDERS

1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

2.1 RESEARCH DATA

2.1.1 SECONDARY DATA

2.1.2 PRIMARY DATA

2.2 MARKET ESTIMATION METHODOLOGY

2.2.1 GLOBAL MARKET ESTIMATION

2.2.1.1 INSIGHTS FROM PRIMARY EXPERTS

2.2.2 SEGMENT ASSESSMENT METHODOLOGY (TOP DOWN APPROACH)

2.3 MARKET GROWTH FORECAST

2.4 DATA TRIANGULATION

2.5 RESEARCH ASSUMPTIONS

2.6 RESEARCH LIMITATIONS

2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 MARKET OVERVIEW

5.1 INTRODUCTION

5.2 MARKET DYNAMICS

5.2.1 DRIVERS

5.2.2 RESTRAINTS

5.2.3 OPPORTUNITIES

5.2.4 CHALLENGES

5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES

5.4 VALUE CHAIN ANALYSIS

5.5 SUPPLY CHAIN ANALYSIS

5.6 ECOSYSTEM ANALYSIS

5.7 TECHNOLOGY ANALYSIS

5.7.1 KEY TECHNOLOGIES

5.7.1.1 POLYMERASE CHAIN REACTION (PCR)

5.7.1.2 NEXT-GENERATION SEQUENCING (NGS)

5.7.2 COMPLIMENTARY TECHNOLOGIES

5.7.2.1 CRISPR/CAS9 GENOME EDITING

5.8 PORTER’S FIVE FORCES ANALYSIS

5.8.1 THREAT OF NEW ENTRANTS

5.8.2 THREAT OF SUBSTITUTES

5.8.3 BARGAINING POWER OF SUPPLIERS

5.8.4 BARGAINING POWER OF BUYERS

5.8.5 INTENSITY OF COMPETITION RIVALRY

5.9 REGULATORY ANALYSIS

5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES & OTHER ORGANIZATIONS

5.9.2 REGULATORY FRAMEWORK

5.10 PRICING ANALYSIS

5.10.1 INDICATIVE PRICE OF CLONING & MUTAGENESIS OFFERINGS, BY KEY PLAYER, 2023

5.10.2 INDICATIVE PRICE OF CLONING & MUTAGENESIS OFFERINGS, BY REGION, 2023

5.11 KEY CONFERENCES AND EVENTS IN 2025-26

5.12 KEY STAKEHOLDERS & BUYING CRITERIA

5.12.1 KEY STAKEHOLDERS IN THE BUYING PROCESS

5.12.2 BUYING CRITERIA FOR END USERS

5.13 IMPACT OF AI/GENERATIVE AI ON CLONING & MUTAGENESIS MARKET

5.14 INVESTMENT AND FUNDING ACTIVITIES

6 CLONING & MUTAGENESIS MARKET, BY OFFERINGS

6.1 INTRODUCTION

6.2 PRODUCT

6.2.1 CLONING KITS

6.2.2 MUTAGENESIS KITS

6.2.3 OTHER PRODUCTS

6.3 SERVICE

7 CLONING & MUTAGENESIS MARKET, BY TECHNIQUE

7.1 INTRODUCTION

7.2 TOPO PCR CLONING

7.3 BLUNT END CLONING

7.4 SEAMLESS CLONING

7.5 SITE-DIRECTED MUTAGENESIS

7.6 OTHER TECHNIQUES

8 CLONING & MUTAGENESIS MARKET, BY APPLICATION

8.1 INTRODUCTION

8.2 RESEARCH

8.3 THERAPEUTIC

8.4 OTHER APPLICATIONS

9 CLONING & MUTAGENESIS MARKET, BY END USER

9.1 INTRODUCTION

9.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES

9.3 CROs & CMOs

9.4 ACADEMIC & RESEARCH INSTITUTES

9.5 DIAGNOSTIC LABORATORIES

10 CLONING & MUTAGENESIS MARKET, BY REGION

10.1 INTRODUCTION

10.2 NORTH AMERICA

10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA

10.2.2 US

10.2.3 CANADA

10.3 EUROPE

10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE

10.3.2 GERMANY

10.3.3 UK

10.3.4 FRANCE

10.3.5 ITALY

10.3.6 SPAIN

10.3.7 REST OF EUROPE

10.4 ASIA PACIFIC

10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC

10.4.2 CHINA

10.4.3 JAPAN

10.4.4 INDIA

10.4.5 AUSTRALIA

10.4.5 SOUTH KOREA

10.4.6 REST OF APAC

10.5 LATIN AMERICA

10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA

10.5.1 BRAZIL

10.5.2 MEXICO

10.5.3 REST OF LATIN AMERICA

10.6 MIDDLE EAST

10.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST

10.6.1 GCC COUNTRIES

10.6.2 REST OF MIDDLE EAST

10.7 AFRICA

10.6.1 MACROECONOMIC OUTLOOK FOR AFRICA

Note: This section will provide market sizes & forecast by phase, service type, therapy area, modality, delivery model, study design, and end user for each region and country.

11 COMPETITIVE LANDSCAPE

11.1 INTRODUCTION

11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2023

11.3 REVENUE SHARE ANALYSIS, 2021-2023

11.4 MARKET SHARE ANALYSIS, 2023

11.5 CLONING & MUTAGENESIS MARKET: COMPANY EVALUATION MATRIX: KEY PLAYER,2023

11.5.1 STARS

11.5.2 EMERGING LEADERS

11.5.3 PERVASIVE PLAYERS

11.5.4 PARTICIPANTS

11.6 COMPANY FOOTPRINT, KEY PLAYERS,2023

11.6.1 COMPANY FOOTPRINT

11.6.2 REGIONAL FOOTPRINT

11.6.3 PRODUCTS FOOTPRINT

11.6.4 TECHNIQUE FOOTPRINT

11.6.5 APPLICATION FOOTPRINT

11.7 COMPANY EVALUATION MATRIX, START-UPS/SMES, 2023

11.7.1 PROGRESSIVE COMPANIES

11.7.2 RESPONSIVE COMPANIES

11.7.3 DYNAMIC COMPANIES

11.7.4 STARTING BLOCKS

11.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023

11.7.5.1 DETAILED LIST OF KEY STARTUPS/ SMES

11.7.5.2 COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS

11.8 BRAND/ SERVICE COMPARATIVE ANALYSIS

11.9 VENDOR VALUATION AND FINANCIAL METRICS OF THE CLONING & MUTAGENESIS MARKET

11.10 COMPETITIVE SCENARIO AND TRENDS

11.9.1 PRODUCT/SERVICE LAUNCHES

11.9.2 DEALS

11.9.3 OTHER DEVELOPMENTS

12 COMPANY PROFILES

12.1 KEY PLAYERS

12.1.1 THERMO FISHER SCIENTIFIC INC. (PPD, INC.)

12.1.2 AGILENT TECHNOLOGIES, INC.

12.1.3 CHARLES RIVER LABORATORIES

12.1.4 GENSCRIPT

12.1.5 NEW ENGLAND BIOLABS

12.1.6 MERCK KGAA

12.1.7 BIO-RAD LABORATORIES

12.1.8 DANAHER CORPORATION

12.1.9 TAKARA BIO

12.1.10 PROMEGA

12.1.11 TRANSGEN BIOTECH CO., LTD.

12.1.12 JENA BIOSCIENCE GMBH

12.1.13 ASSAY GENIE

Note: Above list is an indicative list of companies. Details on business overview, financial information, service portfolio, recent developments, and MarketsandMarkets view will be provided for ~25 companies. These details might not be captured in the case of unlisted companies. The list of players provided is tentative and subject to change during the research.

13 APPENDIX

13.1 DISCUSSION GUIDE

13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL

13.3 AVAILABLE CUSTOMIZATIONS

13.4 RELATED REPORTS

13.5 AUTHOR DETAILS

Note: The given segmentation is tentative and subject to change during the course of research.

Request for detailed methodology, assumptions & how numbers were triangulated.

Please share your problem/objectives in greater details so that our analyst can verify if they can solve your problem(s).

5 5 3 3 4

Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Cloning and Mutagenesis Market: Growth, Size, Share, and Trends

Cloning and Mutagenesis Market - Global Forecast 2030

Cloning and mutagenesis market- global forecast to 2030

Global Cloning and Mutagenesis Market Dynamics

DRIVER: Growing advancements in genomic technologies

RESTRAINT: Complexity of techniques

Recent Developments:

Growth opportunities and latent adjacency in Cloning and Mutagenesis Market

Get recent trends delivered to your inbox

Want to explore hidden markets that can drive new revenue in Cloning and Mutagenesis Market?